Virica has been selected as a project lead for one of NIIMBL | The National Institute for Innovation in Manufacturing Biopharmaceuticals planned projects, which aim to address key opportunities for innovation in biopharmaceutical manufacturing.
NIIMBL is a public-private partnership whose mission is to accelerate biopharmaceutical manufacturing.
Virica, with support from NIIMBL members AstraZeneca and Sartorius Stedim Biotech, aims to increase lentiviral vector production outputs, cut costs, and improve manufacturing efficiency for CAR-T using small-molecule enhancers.